Selumetinib Shrinks Pediatric Tumors, Results of an Early-Phase Clinical Trial

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Brigitte C. Widemann, M.D., acting chief of the National Cancer Institute’s (NCI) Pediatric Oncology Branch, discusses the results of her phase 1 trial, which evaluated the toxicity and safety of selumetinib in patients with the common genetic disorder neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas.